You are here

  • Home
  • Archive
  • Volume 75, Issue 6
  • Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

Citation Tools

Article menu
Clinical and epidemiological research
Extended report
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Takeuchi T, Tanaka Y, Iwasaki M, et al
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study
Annals of the Rheumatic Diseases 2016;75:1057-1064.